Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
182431-12-5
InChi: InChI=1S/C13H12F2N6O
Vet Comp Oncol
Cetirizine
Toxicology of aldicarb
DCC-2618 315920(Varespladib) 182431-12-5Ripretinib, also known as DCC 2618, is a potent, orally active and selective KIT PDGFR inhibitor with potential antineoplastic activity. DCC 2618 targets and binds to both wild type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild type and mutant forms. In May 2020, FDA Approves Qinlock (ripretinib) for
US$ 89.99
US$ 81.99
US$ 139.99
US$ 81.99
US$ 44000.00
Sold : Login>>